Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- Daiichi Sankyo Opens Representative Office in Vietnam
October 6, 2014
- Takeda to Invest in Alfresa Corporation’s Vaccine-Related Subsidiary
October 6, 2014
- Eisai Launches Halaven in Australia
October 3, 2014
- Santen Completes Transfer of Ophthalmology Assets from Merck
October 3, 2014
- Jim Murphy, GM of Alcon US Vision Care, Leads Alcon Japan as New President
October 3, 2014
- MTPC Charges Ahead with Research Lab Overhaul to Buttress Drug Discovery
October 2, 2014
- Daiichi Sankyo Seeks Tuberculosis Indication for Cravit, AGs
October 2, 2014
- MTPC Paid 19.8 Billion Yen to Physicians, Medical Institutions in FY2013
October 2, 2014
- Novartis Pharma Notifies PMDA of Additional 1,299 Unreported Serious ADRs
October 2, 2014
- AZ Starts J-DISCOVER Observational Study of Type 2 Diabetes Management
October 2, 2014
- Sumitomo Dainippon Obtains Patent License from Dnavec for Production of Clinical iPS Cells
October 2, 2014
- Kissei to Spice Up Current Portfolio in Next 3 Years, Launch New Drugs Later
October 1, 2014
- Takeda, MacroGenics Sign Second Agreement to Develop Autoimmune Disease Treatments
October 1, 2014
- Sumitomo Dainippon’s FY2013 Payments to Healthcare Professionals at 13.1 Billion Yen
October 1, 2014
- Kyowa Kirin, Pfizer to Collaborate on Cancer Immunotherapy
October 1, 2014
- Kowa Receives Approval for Glaucoma Treatment Glanatec
October 1, 2014
- AZ Was Concerned with Pfizer’s Possible Takeover Deal Withdrawal Due to US Anti-Inversion Move: CEO
September 30, 2014
- e-Detailing Powerhouse M3 to Establish New Firm Dedicated to CSO Biz
September 30, 2014
- Lixiana OK’d for Stroke Prevention in Japan: Daiichi Sankyo
September 30, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…